Anterogen.Co.,Ltd. announced that it expects to receive KRW 12 billion in funding
April 22, 2020
Share
Anterogen Co.,Ltd. (KOSDAQ:A065660) announced a private placement of 4th series convertible bonds for gross proceeds of KRW 12,000,000,000 on April 23, 2020. The bonds are issued at zero interest rate and will mature on June 12, 2020. The bonds can be 100% converted into shares at a fixed conversion price of KRW 36,550 per share. The conversion period is from April 23, 2021 to March 24, 2023. The transaction will include participation from Neoflux Market-Frontier Secondary Fund for KRW 2,500,000,000, Company K Culture-IC Company K Culture-ICT United Fund T United Fund for KRW 2,500,000,000, Korea Investment & Securities Co., Ltd. on behalf of Tiger Hedge Fund 5-02, Tiger Hedge Fund 5-12, Tiger TRUE Hedge Fund 2, Tiger Kosdaq Venture TRUE Hedge for KRW 4,050,000,000, NH Investment & Securities Co., Ltd. on behalf of , Tiger GEAR UP 12 Hedge Fund , Tiger Mezzanine&Alpha Hedge Fund 202, Tiger Alpha 203 Hedge Fund , Tiger NEW Hedge Fund 2, Tiger GEAR UP Hedge Fund 2, Tiger Kosdaq Venture ALPHA Hedge Fund 2, Tiger Mezzanine Hippo Hedge Fund 001, Tiger Metes Hedge Fund 204, Tiger Hedge Fund 5-03, Tiger TRUST Hedge Fund 3, Tiger MERITHedge Fund 3, Tiger Hedge Fund 5-13, Tiger BALANCE Hedge Fund 3, Leeun Kosdaq Venture Private Securities Investment Trust 1, Leeun Kosdaq Venture Private Securities Investment for KRW 2,500,000,000, Samsung Securities Co.,Ltd. on behalf of : Tiger Hedge Fund 5-31, Tiger Hedge Fund 5-51, Tiger Curves Hedge Fund 1 for KRW 350,000,000, and Mirae Asset Daewoo Co., Ltd. on behalf of Tiger CLASSIC Hedge Fund 4 for KRW 100,000,0000. The transaction has been approved by the board of directors of the company. The transaction is expected to close on April 24, 2020.
ANTEROGEN CO.,LTD. is a Korea-based company mainly engaged in the manufacture of cell therapy products. The Company's product portfolio consists of Cupistem which is used for the treatment of Crohnâs fistula by using autologous adipose-derived mesenchymal stem cells; stem cell conditioned medias (SCMs), SCM2s, and Therastem-dermas which are used for strengthening the function of skin as cosmetic raw materials; Remodullins which are used for the treatment of pulmonary arterial hypertension (PAH) and other products which are used for testing services. The Company distributes its products within domestic market.